Men with non-metastatic castration resistant prostate cancer (nmCRPC) tend to have many additional co-morbidities, given that they are most likely older. Non-metastatic castrate resistant prostate cancer needs to be actively treated. Still, the many co-morbidities, including coronary issues, make treatment more difficult.
A recent study, the ARAMIS trial (NCT02200614), showed that men with nmCRPC who have multiple co-morbidities responded well to the androgen receptor pathway drug darolutamide (Nubeqa). This study was presented at the 2022 ASCO Genitourinary Cancers Symposium.1
The trial included over 1,500 men. Half of the subject men had a minimum of 6 or more co-morbidities of significance. They were also taking ten or more drugs daily.
The trial showed, despite the very high number of co-morbidities suffered by the study population, based on CT scans and technetium bone scans, the men taking Nubeqa had a significant delay in radiographic progression of nearly two years. Radiographic progression means that scans showed additional cancer spread or growth. These same men also had a statistically significant, greater-than-a-year improvement in survival despite crossovers.
Men with non-metastatic castrate resistant prostate cancer, whether or not they have co-morbidities, should discuss with their treating clinicians adding darolutamide (Nubeqa) to their standard hormone therapy. Nubeqa is effective in extending a person's life and delaying radiographic progression, even in men with multiple complex co-morbidities.
Reference
1. Fizazi K, Shore ND, Smith MR, et al. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with co-morbidities and concomitant medications from ARAMIS. Paper presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022; San Francisco, California. Abstract #256
